Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD

Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech’s Series B round will finance clinical tests of two programs, each addressing a different stage of the disease….

Read More

Continuous Process Improvement: The Secret to Navigating Early-Phase Drug Development 

Deploying a robust continuous improvement methodology is especially beneficial in the earliest phases of drug development. It can help ensure the delivery of high-quality, reliable, timely bioanalytical and clinical data to make informed decisions about either moving on to the next drug development milestone or pivoting to another strategy.  The post Continuous Process Improvement: The…

Read More